p53 is a common denominator among human cancers. How was it discovered? What are the persistent questions about its function? Aa Aa Aa It seems nearly impossible for a normal cell to become a ...

Malfunction of the p53 pathway is an almost universal hallmark of human tumours. [1,2] Somatic mutation of TP53 that results in the absence or dysfunction of p53 is one of the most common ...

That is below the 30% rate reported at an interim stage of the study at the International Liver Congress earlier this year, but still sufficient for GSK to take the drug forward into a phase 3 ...

Merely a month into an FDA approval for a broad first-line endometrial cancer population, Merck’s Keytruda has some company.

British drugmaker GSK cut its forecast for 2024 vaccine sales on Wednesday after quarterly revenue from its blockbuster ...

Genomic testing matters in endometrial cancer both for prognostication and therapeutic selection, but there's work to do in ...

GSK raised its full-year guidance after second quarter core earnings rose 13%, helped by higher sales in oncology, HIV and ...

GSK (GSK) stock gained as the company received the FDA nod to expand the label for its immunotherapy Jemperli targeted at ...

GSK’s Fundamentals And Financial Position GSK’s revenue has risen at an average annual rate of 7.9% from £24.3 billion in 2020 to £30.3 billion in 2023, aided by its specialty medicines ...

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the ...

TP53I3 = tumour protein p53 inducible protein 3. p53 lies at the hub of a vast signalling network. Polymorphisms in upstream activators, repressors or downstream effectors of p53 might ...